ACTINIUM PHARMACEUTICALS INC

ATNMNYSE AMERICAN

🏆 #3618 by market capEarnings Nov 13US Equity

$0.79▲ $0.02 (+2.97%)

🌙 After hours$0.79▼ 0.39%Regular close · extended-hours price shown

1h—

24h▲ 3.0%

7d▲ 5.7%

14d▼ 5.5%

30d▼ 15.3%

1y▼ 48.2%

🏦Market Cap

$25M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

278.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $0.78 – $0.80
52-Week Range: $0.74 – $1.81
Volume: $2.62B
Avg Volume: $1.92B
Shares Outstanding: 31.4M
Next Earnings: Oct 6, 2026

Fundamentals Snapshot

Annual Revenue: $90,000
Last Q Revenue: $35M
P/E Ratio: —
P/S Ratio: 278.0x
EPS (TTM): $-0.75
Dividend Yield: —

Why Investors Own ATNM

✓High-growth profile — revenue up -7.6% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$90,000▼ −9.4% YoY

Gross Margin (TTM)

47.6%▲ +2.1% YoY

Operating Income (TTM)

$27,090▼ −9.4% YoY

Free Cash Flow (TTM)

$13,140▼ −9.4% YoY

About ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

🦦